Phaseline

Targets › CD79B

CD79B (B-cell antigen receptor complex-associated protein beta chain): drug programs, companies and trials

5 programs from 5 companies in 49 trials: 32 Phase 2, 12 Phase 1, 4 Phase 3, 1 Phase 4; Oncology; next expected readout Feb 2027.

Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. (UniProt, P40259)

Open in Phaseline: the race on CD79B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RochePolatuzumab vedotin
B-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhibitor
CD79B, TubulinPhase 3Non-Hodgkin Lymphoma; Large B-Cell Lymphoma; B-cell Non-Hodgkin Lymphoma; Non-Hodgkins Lymphoma …Feb 2027
Memorial Sloan Kettering Cancer CenterPolatuzumab
Anti-CD79B antibody-drug conjugate
CD79BPhase 2Diffuse Large B Cell Lymphoma (DLBCL)Jan 2028
Beijing Tongren HospitalPolatuzumab
Anti-CD79B antibody-drug conjugate
CD79BPhase 2Diffuse Large B Cell Lymphoma (DLBCL)Feb 2028
Johnson & Johnson (Janssen)JNJ-80948543
T-cell redirecting trispecific antibody against CD79b, CD20, and CD3
CD79B, CD20, CD3Phase 1Lymphoma, Non-HodgkinMar 2027
Marcela V. Maus, M.D.,Ph.D.CD79b-19 CAR T cells
CAR-T cells targeting CD79b and CD19
CD79B, CD19Phase 1Non-hodgkin LymphomaAug 2027

Conditions

Diffuse Large B-Cell Lymphoma (7) Diffuse Large B-Cell Lymphoma (DLBCL) (4) Lymphoma, Non-Hodgkin (3) Diffuse Large B Cell Lymphoma (DLBCL) (3) DLBCL (2) Non-hodgkin Lymphoma (2) Lymphoma (2) Non-Hodgkin Lymphoma (1) Large B-Cell Lymphoma (1) B-cell Non-Hodgkin Lymphoma (1) Non-Hodgkins Lymphoma (1) Refractory Non-Hodgkin Lymphoma (1)

Modalities

small molecule (2), mixed (2), antibody (1)

Companies

Johnson & Johnson (Janssen) (1) Memorial Sloan Kettering Cancer Center (1) Beijing Tongren Hospital (1) Roche (1) Marcela V. Maus, M.D.,Ph.D. (1)

Related targets

CD20 (1) CD3 (1) Tubulin (1) CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.